IA-2 (Insulinoma-Associated Protein 2) Autoantibodies

IA-2 autoantibodies (IA-2A) are autoantibodies directed against the insulinoma-associated protein 2 (IA-2), a tyrosine phosphatase protein found in pancreatic beta cells. These antibodies are primarily associated with Type 1 Diabetes (T1D) and are used as a marker for diagnosing and predicting the disease.

---

Key Features of IA-2 Autoantibodies (IA-2A):

1. Marker of Beta Cell Autoimmunity – IA-2A targets pancreatic beta cells, leading to their destruction and decreased insulin production.
2. Common in Type 1 Diabetes – Found in 50–75% of newly diagnosed T1D patients.
3. Early Indicator of Type 1 Diabetes Risk – IA-2A can appear years before symptoms, especially in people with a family history of T1D.
4. Usually Found with Other Autoantibodies – IA-2A is often detected alongside:
   • GAD65 autoantibodies (GADA)
   • Insulin autoantibodies (IAA)
   • Zinc Transporter 8 autoantibodies (ZnT8A)

---

Clinical Significance of IA-2A Testing:

✅ Diagnosis of Type 1 Diabetes

• Helps differentiate Type 1 Diabetes (autoimmune) from Type 2 Diabetes (non-autoimmune).

✅ Risk Assessment in Relatives of T1D Patients

• Higher IA-2A levels indicate a greater risk of developing T1D in the future.

✅ Screening in Latent Autoimmune Diabetes in Adults (LADA)

• Helps identify LADA, a slow-progressing form of Type 1 Diabetes that appears in adults.

✅ Monitoring Disease Progression

• IA-2A levels tend to decrease over time after complete beta cell destruction.

---

IA-2A Results Interpretation:

---

IA-2A vs. Other Diabetes Autoantibodies:

---

Key Takeaways:

✔ IA-2A is a strong predictor of Type 1 Diabetes.
✔ Higher levels indicate an increased risk of developing T1D.
✔ Used alongside other autoantibodies for better accuracy.
✔ Helps distinguish autoimmune diabetes (T1D & LADA) from Type 2 Diabetes.